Overview

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a single-center, prospective, single-arm, open-label phase II study
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborator:
Novartis